Generate Biomedicines, Inc. Common Stock (GENB) is a publicly traded the market company. As of October 13, 2026, GENB trades at $12.75 with a market cap of $1.78B and a P/E ratio of -26.77. GENB moved -11.42% today. Year to date, GENB is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $11.00 to $22.67. Analyst consensus is strong buy with an average price target of $26.00. Rallies surfaces GENB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
GENB financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. GENB recently traded at $12.75. Market cap is $1.78B. P/E ratio is -26.77. Revenue is $6.31M.
| Metric | Value |
|---|---|
| Price | $12.75 |
| Market Cap | $1.78B |
| P/E Ratio | -26.77 |
| EPS | $-0.52 |
| Dividend Yield | 0.00% |
| 52-Week High | $22.67 |
| 52-Week Low | $11.00 |
| Volume | 857.47K |
| Avg Volume | 0 |
| Revenue (TTM) | $6.31M |
| Net Income | $-67.25M |
| Gross Margin | 0.00% |
3 analysts cover GENB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $26.00.